Improved Quality of Glycemic Control and Reduced Glycemic Variability with Use of Continuous Glucose Monitoring
Open accessThe DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: We evaluated effects of unmasking of continuous display of continuous glucose monitoring (CGM) on quality of glycemic control and glycemic variability. METHODS: We reanalyzed CGM data from 85 patients using a 7-day glucose sensor. Glucose values were "masked" during the first week but "unmasked" during the next 2 weeks. We evaluated 48 criteria for quality of glycemic control, including mean glucose, SD, percentage of values within-, above- or below- specified ranges, Schlichtkrull's M(100) index, mean amplitude of glycemic excursion (MAGE), mean of daily differences (MODD), the J index, "Index of Glycemic Control" (IGC), Hyperglycemia Index, Hypoglycemia Index, High Blood Glucose Index (HBGI), Low Blood Glucose Index (LBGI), average daily risk range (ADRR), GRADE scores, and CONGA(n). We calculated SD values between daily means, between days-within time points, within days, between time points (for the average glucose profile for several days), and within series for time segments of arbitrary length. RESULTS: Unmasking CGM displays resulted in rapid, highly statistically significant improvement in 29 indices, including percentage within, percentage above, and percentage below target range, mean glucose, SD, SD of daily means, MODD, M(100), IGC, GRADE, HBGI, and J index. Both hyperglycemia and hypoglycemia improved during the first week after unmasking; further improvement in hypoglycemia was seen during the following week. Results obtained using multiple criteria were consistent and highly correlated. CONCLUSIONS: Continuous access to display of CGM sensors dramatically improved 29 indices of glycemic control and glycemic variability.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Continuous glucose monitoring and intensive treatment of type 1 diabetes
(2008) · New England Journal of Medicine · doi:10.1056/nejmoa0805017 · Cited by 1,559
Ceriello, A., Esposito, K., Piconi, L., Ihnat, M. A., Thorpe, J. E., Testa, R., Boemi, M., & Giugliano, D. (2008) · Diabetes · doi:10.2337/db08-0063 · Cited by 1,310
Deiss, D., Bolinder, J., Riveline, J.-P., Battelino, T., Bosi, E., Tubiana-Rufi, N., Kerr, D., & Phillip, M. (2006) · Diabetes Care · doi:10.2337/dc06-1134 · Cited by 539
Bailey, T. S., Zisser, H. C., & Garg, S. K. (2007) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2007.0205 · Cited by 159 · cited 4×
“Criteria such as the Hypoglycemia Index and ‘‘percentage of observations below 50 mg = dL’’ showed relatively large percentage change but were accompanied by larger standard errors for the difference between periods, making them less sensitive to the effect of unmasking of real-time displays of CGM.”
InfluentialSelf-citation
Cited by
International consensus on use of continuous glucose monitoring
Danne, T., Nimri, R., Battelino, T., Bergenstal, R. M., Close, K. L., DeVries, J. H., Garg, S., Heinemann, L., Hirsch, I., Amiel, S. A., et al. (2017) · Diabetes Care · doi:10.2337/dc17-1600 · Cited by 2,069
Self-citationBergenstal, R. M., Ahmann, A. J., Bailey, T., Beck, R. W., Bissen, J., Buckingham, B., Deeb, L., Dolin, R. H., Garg, S. K., Goland, R., et al. (2013) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2013.0051 · Cited by 307
Wright, L. A.-C., & Hirsch, I. B. (2017) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2017.0029 · Cited by 178
Bergenstal, R. M. (2015) · Diabetes Care · doi:10.2337/dc15-0099 · Cited by 140
Does Glycemic Variability Impact Mood and Quality of Life?
Penckofer, S., Quinn, L., Byrn, M., Ferrans, C., Miller, M., & Strange, P. (2012) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2011.0191 · Cited by 138
Metadata
- Authors
- Rodbard, D., Bailey, T., Jovanovic, L., Zisser, H., Kaplan, R., & Garg, S. K.
- Venue
- Diabetes Technology & Therapeutics
- Publisher
- SAGE Publications
- Published
- 2009-11
- Volume
- 11
- Issue
- 11
- Pages
- 717-723
- ISSN
- 1520-9156 (ISSN-L)
- 1557-8593
- OpenAlex
- W2008908415
- Cited by
- 131
- References
- 4
- FWCI
- 6.31
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.